Divi's Laboratories Ltd
NSE:DIVISLAB

Watchlist Manager
Divi's Laboratories Ltd Logo
Divi's Laboratories Ltd
NSE:DIVISLAB
Watchlist
Price: 5 886.75 INR 1.81% Market Closed
Market Cap: 1.6T INR
Have any thoughts about
Divi's Laboratories Ltd?
Write Note

Divi's Laboratories Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Divi's Laboratories Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Divi's Laboratories Ltd
NSE:DIVISLAB
Gross Profit
â‚ą48.9B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Gross Profit
â‚ą20.6B
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Gross Profit
â‚ą25.4B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Vimta Labs Ltd
NSE:VIMTALABS
Gross Profit
â‚ą2.4B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
12%
I
Innova Captab Ltd
NSE:INNOVACAP
Gross Profit
â‚ą3.3B
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Divi's Laboratories Ltd
Glance View

Market Cap
1.6T INR
Industry
Life Sciences Tools & Services

Divi's Laboratories Ltd. has carved an enviable niche for itself in the global pharmaceutical industry, with its origins tracing back to 1990 in Hyderabad, India. With a steadfast focus on research and development, the company stands as a formidable force in the Active Pharmaceutical Ingredients (APIs) and Intermediates manufacturing sector. Its strategy hinges on two complementary business segments: generic APIs and custom synthesis of APIs and intermediates. By catering to a broad spectrum of therapeutic areas, from cardiovascular ailments to pain management, Divi's capitalizes on economies of scale and technological innovation to produce cost-effective, high-quality pharmaceutical products. This strategy not only aligns with the company’s expertise in process development and chemical synthesis but also positions it as a key supplier to major pharmaceutical companies worldwide, providing a significant portion of their API requirements. The crux of Divi's financial engine lies in its custom synthesis segment, where it forms strategic alliances with global pharmaceutical giants, offering end-to-end solutions from drug discovery to commercialization. This vertical is fueled by long-term contracts that bolster the company’s revenue visibility and profitability. Meanwhile, the generic APIs segment benefits from the rising global demand for affordable healthcare solutions, particularly in emerging markets. Divi’s Laboratories leverages its state-of-the-art manufacturing facilities, which are compliant with international regulatory standards, to ensure efficient production cycles and maintain a consistent supply chain. Through its blend of innovative R&D, a robust manufacturing backbone, and strategic partnerships, Divi's Laboratories adeptly navigates the complexities of the pharmaceutical industry, making it a stalwart in the sector's supply chain ecosystem.

DIVISLAB Intrinsic Value
3 256.64 INR
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Divi's Laboratories Ltd's Gross Profit?
Gross Profit
48.9B INR

Based on the financial report for Jun 30, 2024, Divi's Laboratories Ltd's Gross Profit amounts to 48.9B INR.

What is Divi's Laboratories Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
9%

Over the last year, the Gross Profit growth was 12%.

Back to Top